Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery



Status:Terminated
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/19/2018
Start Date:September 2014
End Date:June 8, 2016

Use our guide to learn which trials are right for you!

Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy

This randomized phase II trial studies how well regorafenib works in treating patients with
cancer of the esophagus or gastroesophageal junction that has spread from where it started to
nearby tissue or lymph nodes and have completed chemoradiation therapy and surgery.
Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.

PRIMARY OBJECTIVES:

I. To compare the disease-free survival (DFS) for patients with resected esophageal and
gastroesophageal (GE) junction adenocarcinoma treated with regorafenib vs. placebo in the
adjuvant setting.

SECONDARY OBJECTIVES:

I. To compare the safety profile of adjuvant regorafenib vs. placebo in patients with locally
advanced resectable esophageal and GE junction adenocarcinoma.

II. To compare the overall survival (OS) for patients with resected esophageal and GE
junction adenocarcinoma treated with regorafenib vs. placebo in the adjuvant setting.

III. To compare the DFS in those patients that receive at least 1 cycle of therapy.

IV. To collect tumor samples for future genomic analysis to explore the biology of locally
advanced esophageal and GE junction adenocarcinoma.

V. DFS will be compared between the arms from the time of surgery as well.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Within 6-12 weeks after surgery, patients receive regorafenib orally (PO) once daily
(QD) on days 1-21.

ARM II: Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21.

In both arms, courses repeat every 28 days for up to 1 year in the absence of disease
progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years, and
every 6 months for up to 5 years.

Inclusion Criteria:

- Histological confirmation of node positive (any T stage N1-3) proximal esophageal,
distal esophagus or gastroesophageal (GE) junction adenocarcinoma (Siewert I, II, or
III) after completing preoperative chemoradiation and surgery; supporting pathology
report sufficient for registration; available tumor tissue from endoscopic biopsies
prior to preoperative chemotherapy (chemo)/radiation therapy (RT), and tumor from
surgical specimens will be submitted to Academic and Community Cancer Research United
(ACCRU), but not be required prior registration; Note: if tissue is depleted, patient
will still be eligible after discussion with the physician

- Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) =< 28 days of
study registration negative for disease recurrence

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

- Absolute neutrophil count (ANC) >= 1500/mm^3

- Platelet count >= 100,000/mm^3

- Total bilirubin =< 1.5 x the upper limits of normal (ULN)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5
x ULN for subjects with liver involvement of their cancer)

- Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver
involvement of their cancer)

- Lipase =< 1.5 x the ULN

- Serum creatinine =< 1.5 x the ULN

- International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN;
Note-subjects who are therapeutically treated with an agent such as warfarin or
heparin will be allowed to participate provided that their medication dose and INR/PTT
are stable; close monitoring (day 1 of each cycle) is mandatory; if either of these
values is above the therapeutic range, the doses should be modified and the
assessments should be repeated weekly until they are stable

- Negative pregnancy test done =< 7 days prior to registration, for women of
childbearing potential only

- Provide informed written consent

- Willing to return to enrolling institution for follow-up (during the Active Monitoring
Phase of the study)

- Able to swallow and retain oral medications and begin therapy within 6 to 12 weeks
post-surgery

- Provide blood samples for the mandatory correlative research purposes

Exclusion Criteria:

- Presence of metastatic or recurrent disease

- R1 or R2 resection

- Patients who have not recovered from serious adverse events (as determined by treating
doctor of medicine [MD]) related to surgery

- Uncontrolled hypertension (systolic pressure > 140 mm Hg or diastolic pressure > 90 mm
Hg on repeated measurement) despite optimal medical management per physician
discretion

- Active or clinically significant cardiac disease including:

- Congestive heart failure - New York Heart Association (NYHA) > class II

- Active coronary artery disease

- Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or
digoxin

- Unstable angina (anginal symptoms at rest), new-onset angina < 3 months before
randomization, or myocardial infarction within 6 months before randomization

- Evidence or history of bleeding diathesis or coagulopathy

- Any hemorrhage or bleeding event >= National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI CTCAE) version 4 grade 3 =< 4 weeks prior to
registration

- Prior cancers < 3 years, with the exception of in-situ cervical cancer, low grade
prostate cancer and basal or squamous cell skin cancers

- Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular
accident (including transient ischemic attacks) deep vein thrombosis or pulmonary
embolism =< 6 months prior to registration

- Receiving any medications or substances that are strong or moderate inhibitors of
cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4); use of strong or
moderate inhibitors are prohibited =< 7 days to registration

- Receiving any medications or substances that are inducers of CYP3A4; use of inducers
are prohibited =< 7 days prior to registration
We found this trial at
10
sites
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Konstantin H Dragnev, MD
Phone: 603-650-4428
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
New Orleans, Louisiana 70121
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Yelena Janjigian, M.D.
Phone: 646-888-4186
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Omaha, Nebraska 68106
Principal Investigator: Gamini Soori, MD
Phone: 402-991-8070
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Harry H Yoon, M.D.
Phone: 855-776-0015
?
mi
from
Rochester, MN
Click here to add this to my saved trials
4126 N. Holland Sylvania Road, Suite 105
Toledo, Ohio 43623
419-479-5605
Toledo Clinic Cancer Centers-Toledo Our doctors evaluate and make recommendations regarding cancer treatment for newly...
?
mi
from
Toledo, OH
Click here to add this to my saved trials
602 W University Ave
Urbana, Illinois 61801
(217) 383-3010
Principal Investigator: James R. Egner, M.D.
Phone: 217-383-3516
Carle Cancer Center Carle Cancer Center delivers comprehensive care through leading-edge technology and advanced research,...
?
mi
from
Urbana, IL
Click here to add this to my saved trials
?
mi
from
Wichita, KS
Click here to add this to my saved trials
Medical Center Boulevard
Winston-Salem, North Carolina 27157
336-716-2255
Comprehensive Cancer Center of Wake Forest University Our newly expanded Comprehensive Cancer Center is the...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials